Omvoh (Mirikizumab) for Crohn's Disease: A Patient Guide

Mirikizumab for Crohn's disease became a reality on January 15, 2025, when the FDA approved Omvoh for adults with moderately to severely active Crohn's - making it the newest IL-23 inhibitor to join a drug class that is reshaping how we treat this condition (7). Whether you have been through multiple biologics without lasting relief or are just beginning to explore advanced therapies with your gastroenterologist, this guide breaks down what the clinical evidence actually shows, how dosing works, what side effects to watch for, and how Omvoh fits alongside other treatment options.

Key Takeaways

• Omvoh (mirikizumab) was FDA-approved on January 15, 2025 for moderately to severely active Crohn's disease, expanding an earlier 2023 approval for ulcerative colitis (7).
• In the VIVID-1 trial, 53% of patients on mirikizumab achieved clinical remission at one year, compared with 36% on placebo (1).
• Endoscopic response at week 52 was 46% for mirikizumab versus 23% for placebo, meaning nearly twice as many patients showed visible healing of the intestinal lining (1).
• Three-year data from VIVID-2 showed 92.4% of early endoscopic responders maintained clinical remission, suggesting durable benefit over time (3).
• Fatigue improvement was significant: 46.3% of mirikizumab patients had meaningful FACIT-Fatigue gains at one year versus 20.1% on placebo (4).
• Dosing starts with three IV infusions over 12 weeks, then transitions to subcutaneous self-injections every 4 weeks at home (7).

What Is Omvoh (Mirikizumab) and How It Works

Mirikizumab is a humanized monoclonal antibody that targets and blocks the p19 subunit of interleukin-23 (IL-23), a chemical messenger that plays a central role in driving intestinal inflammation in Crohn's disease. By neutralizing IL-23, Omvoh interrupts a chain reaction that would otherwise recruit waves of immune cells into the gut wall, causing the tissue damage, ulceration, and symptoms that define a flare.

The IL-23p19 pathway in plain language

Think of IL-23 as an alarm signal that tells certain immune cells - specifically a group called Th17 cells - to ramp up inflammation in your intestines. In a healthy immune system, IL-23 plays a useful role in fighting infections. But in Crohn's disease, this pathway gets stuck in overdrive, continuously fueling damage even when there is no actual threat. Omvoh essentially intercepts that alarm, quieting the signal without shutting down the entire immune system.

As we explored in our overview of IL-23 inhibitors for Crohn's disease, this class of drugs has emerged as one of the most promising treatment strategies in IBD because it targets a root cause of inflammation rather than a downstream effect.

How Omvoh differs from anti-TNF and other biologics

Understanding where Omvoh fits on the treatment landscape helps you have more productive conversations with your GI team:

• Anti-TNFs (infliximab, adalimumab, certolizumab): Block tumor necrosis factor alpha, a broad inflammatory molecule. Effective for many patients but carry risks of infections and loss of response over time.
• Ustekinumab (Stelara): Blocks both IL-12 and IL-23 together. Mirikizumab is more selective - it blocks only IL-23 while leaving IL-12 intact, which may preserve a broader range of normal immune defenses.
• Risankizumab (Skyrizi): Also targets IL-23p19 selectively, placing it in the same class as Omvoh. The key practical differences are in dosing frequency and administration schedule.
• Guselkumab (Tremfya): Another selective IL-23p19 inhibitor, and as we detailed in our Tremfya patient guide, it offers both subcutaneous and intravenous induction options.
• JAK inhibitors (upadacitinib/Rinvoq): Oral pills that work inside cells. Fast-acting but carry distinct safety considerations including a boxed warning.

For a broader look at choosing among these options, our best biologic decision guide covers the full landscape.

Who Qualifies for Omvoh and How It Is Given

The FDA approved mirikizumab on January 15, 2025 for adults with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant of corticosteroids, immunomodulators, or biologic therapies such as TNF blockers (7). In practical terms, if your current treatment is no longer keeping your Crohn's under control, Omvoh may be an option worth discussing with your doctor.

FDA-approved patient population

The approval specifically covers adults - the drug has not been studied or approved for pediatric Crohn's patients at this time. Candidates include those who have tried and failed conventional therapies or other biologics. Your gastroenterologist will evaluate your individual disease activity, treatment history, and overall health to determine whether Omvoh is appropriate.

Induction and maintenance dosing

Omvoh uses a two-phase approach:

• Induction (weeks 0, 4, and 8): Three intravenous infusions of 900 mg, each given over at least 90 minutes at an infusion center. Plan for roughly two hours per visit, including a short observation period afterward.
• Maintenance (starting at week 12, then every 4 weeks): 300 mg subcutaneous injections, delivered as two consecutive shots (one of 100 mg and one of 200 mg). After training from your care team, these can be self-administered at home.

The transition from IV infusions to home-based injections is a practical advantage for many patients. The infusion visits during induction give your medical team time to monitor your initial response, while the switch to subcutaneous maintenance means fewer clinic visits over the long run.

How Well It Works: VIVID-1 Trial Results

In the VIVID-1 trial, 53% of mirikizumab-treated patients achieved clinical remission at week 52, compared with 36% on placebo (1). This was a large, rigorous study - and the results position Omvoh firmly among the more effective biologic options now available.

Study design and patient population

VIVID-1 was a global phase 3, randomized, double-blind, double-dummy, placebo-controlled and active-controlled study enrolling 1,150 adults with moderate-to-severe Crohn's disease (2). It included an ustekinumab (Stelara) comparator arm, making it one of the few modern Crohn's trials to pit a new drug against an established biologic head-to-head rather than just against placebo. As we noted in our Skyrizi vs. Stelara comparison, this kind of direct comparison is extremely valuable for real-world treatment decisions.

Clinical remission and endoscopic healing

The headline results paint a promising picture:

• Clinical remission at week 52: 53% on mirikizumab vs. 36% on placebo (1)
• Endoscopic response at week 52: 46% on mirikizumab vs. 23% on placebo (1)
• Early endoscopic improvement at 3 months: 32% on mirikizumab vs. 11% on placebo (1)

That early endoscopic improvement at three months is worth highlighting. Visible healing of the intestinal lining is one of the strongest predictors of long-term outcomes in Crohn's disease, and seeing meaningful improvement that early in treatment is encouraging.

Comparison with Stelara (ustekinumab)

Mirikizumab met non-inferiority to ustekinumab for clinical remission at week 52, meaning it performed at least as well (2). Where it went further: mirikizumab showed statistically superior reductions in fecal calprotectin and C-reactive protein (CRP) - two objective markers of intestinal inflammation (2). Lower fecal calprotectin in particular is associated with deeper mucosal healing, which many gastroenterologists now consider the treatment target that matters most.

Three-year durability: VIVID-2 extension

For those wondering whether the benefits hold up over time, the VIVID-2 open-label extension provides reassuring answers. Among patients who achieved endoscopic response at year one, 92.4% remained in clinical remission at three years and 91.2% maintained steroid-free clinical remission (3). Those numbers suggest that for patients who respond well early on, mirikizumab can deliver durable, sustained disease control.

Fatigue, Quality of Life, and Bowel Urgency Improvements

Anyone living with Crohn's knows that remission on paper does not always mean feeling well in practice. That is why the fatigue, quality of life, and bowel urgency data from VIVID-1 matter just as much as the remission rates.

FACIT-Fatigue results

Fatigue is one of the most common and disabling symptoms patients report, even when inflammation appears controlled. In VIVID-1:

• At week 12, 43% of mirikizumab patients achieved meaningful fatigue improvement (measured by the FACIT-Fatigue scale) compared with 31.2% on placebo (4).
• At week 52, 46.3% of mirikizumab patients had a 6-point or greater FACIT-Fatigue improvement versus 20.1% on placebo (4).

These are not small differences. In our community, fatigue often ranks as the symptom that most interferes with daily life, relationships, and work. Having a treatment that measurably addresses it alongside controlling inflammation is a meaningful advantage.

IBDQ, SF-36, and work productivity

Beyond fatigue, researchers measured quality of life using multiple validated tools - the Inflammatory Bowel Disease Questionnaire (IBDQ), the SF-36 health survey (both physical and mental health components), and the EQ-5D-5L visual analog scale. All improved significantly at both week 12 and week 52 compared with placebo (p less than 0.001) (5).

Work productivity also improved. Patients on mirikizumab showed reductions in absenteeism, presenteeism (being at work but impaired), activity impairment, and overall work productivity loss at week 12, with gains sustained through week 52 (5). For many of us, the ability to work reliably and plan our days without fear of sudden disruption is one of the most tangible markers of treatment success.

Bowel urgency at three years

The VIVID-2 extension also tracked bowel urgency - that sudden, intense need to find a bathroom that can be one of the most anxiety-provoking aspects of Crohn's. Among long-term responders, 82.1% reported meaningful improvement in bowel urgency and 71.7% achieved bowel urgency remission at three years (3). For many patients, that level of control can transform daily routines, travel, and social confidence.

Side Effects, Safety Warnings, and Pre-Treatment Screening

Every biologic carries trade-offs between benefit and risk. Here is what the clinical evidence shows about mirikizumab's safety profile, along with practical steps to stay safe during treatment.

Common adverse reactions

The most common side effects reported in at least 5% of patients include (6):

• Upper respiratory infections (colds, sinus infections)
• Injection site reactions (redness, swelling, or discomfort at the shot site)
• Headache
• Joint pain (arthralgia)
• Elevated liver enzymes (usually detected through blood tests, often without symptoms)

For context, serious adverse events in VIVID-1 were actually less common in the mirikizumab group (10.3%) compared with placebo (17.1%), and comparable to the ustekinumab group (10.7%) (2). This suggests a favorable overall safety profile, though individual experiences vary.

Serious warnings and precautions

The prescribing information includes warnings for (6):

• Serious allergic reactions: Rash, hives, or swelling. Stop the drug and seek medical attention if these occur during or after an infusion.
• Infections, including tuberculosis reactivation: Like all biologics that modulate the immune system, mirikizumab may increase the risk of infections. Report any persistent fever, cough, or signs of infection to your care team promptly.
• Hepatotoxicity (liver injury): Cases of elevated liver enzymes and liver injury have been reported. Regular blood monitoring is standard during treatment.

Screening before starting Omvoh

Before your first infusion, your doctor should order:

• Tuberculosis (TB) testing: A skin test or blood test to rule out latent TB before starting any immunosuppressive biologic.
• Hepatitis B and C screening: To check for viral hepatitis that could reactivate during treatment.
• Baseline liver function tests: To establish a reference point for monitoring during therapy.
• Review of current infections: Any active infection should be treated before beginning Omvoh.

Live vaccines should be avoided while on mirikizumab. If possible, complete recommended vaccinations - including shingles, measles-mumps-rubella, and any other live vaccines - before starting treatment. Inactivated vaccines (such as the annual flu shot) are generally safe to receive during treatment. Healthcare systems and vaccination schedules vary by country, so discuss timing with your local care team.

When to call your doctor during treatment: Contact your care team promptly if you notice a persistent cough or fever, rash or hives with swelling, jaundice (yellowing of the skin or eyes) or dark urine, or unusual fatigue combined with abdominal discomfort.

Omvoh Compared with Other Biologics for Crohn's Disease

Choosing a biologic is rarely straightforward, and many patients reasonably want to understand how Omvoh stacks up against alternatives.

IL-23 inhibitors vs anti-TNF and JAK options

The IL-23 inhibitor class - which now includes Omvoh, Skyrizi (risankizumab), and Tremfya (guselkumab) - generally shows favorable safety profiles compared with older anti-TNF drugs. For patients who have failed anti-TNF therapy or cannot take it, IL-23 inhibitors have become a first-line consideration among advanced therapies.

Compared with JAK inhibitors like upadacitinib, IL-23 inhibitors lack the convenience of an oral pill but avoid the class-wide cardiovascular and malignancy warnings that JAK drugs carry. Each approach has trade-offs, and the right choice depends on your personal circumstances.

When Omvoh may make sense

Your GI team may consider Omvoh in several scenarios:

• Anti-TNF failure: You tried infliximab, adalimumab, or another TNF blocker and it stopped working or caused side effects.
• Transition from Stelara: The VIVID-1 non-inferiority result suggests Omvoh is a reasonable consideration if you are losing response to ustekinumab, although head-to-head switching studies are still limited.
• Preference for a specific dosing rhythm: Omvoh's maintenance schedule is every 4 weeks subcutaneously, compared with Skyrizi's quarterly injections. Some patients prefer more frequent, smaller-dose injections; others prefer less frequent dosing. For a deeper comparison, our Skyrizi vs. Stelara article covers several of these practical differences across the IL-23 class.
• Comorbid conditions: If you also have psoriasis or psoriatic arthritis, mirikizumab may address both, since it is already approved for plaque psoriasis.

Ultimately, the decision should weigh your prior biologic history, comorbidities, dosing preference, and personal risk tolerance. Our best biologic decision guide walks through these considerations in detail.

Cost, access, and manufacturer support

Like all biologics, Omvoh carries a significant price tag. Insurance step therapy requirements may mean your plan requires trying an anti-TNF before covering an IL-23 inhibitor. If your insurer initially denies coverage, ask your GI team to help with prior authorization and appeals - many practices have dedicated staff for this process.

Eli Lilly offers the Omvoh Together patient support program, which includes copay assistance for eligible commercially insured patients, help navigating insurance coverage, and connections to independent financial assistance programs. In countries outside the United States, availability, pricing, and patient support programs vary - check with your local healthcare system or patient advocacy organization for current access information.

Frequently Asked Questions

Is mirikizumab safe for long-term use?

Three-year data from the VIVID-2 extension showed that 92.4% of early responders maintained clinical remission and the safety profile remained consistent with no new safety signals emerging (3). While longer follow-up will continue to build the evidence base, the available data are encouraging for sustained use.

How long does it take for Omvoh to start working?

Some patients see endoscopic improvement as early as 3 months - in VIVID-1, 32% had early endoscopic response at week 12 versus 11% on placebo (1). Symptom relief may begin during the induction phase, but the full effect typically builds over the first 6 to 12 months.

Can I self-inject Omvoh at home?

Yes. After completing the three IV infusions during the 12-week induction phase, maintenance dosing transitions to subcutaneous injections that can be self-administered at home. Your care team will train you on injection technique before you start. Each maintenance dose involves two consecutive injections (100 mg and 200 mg).

What is the difference between Omvoh and Skyrizi?

Both are selective IL-23p19 inhibitors, so they target the same pathway. The main practical differences are in dosing schedules: Omvoh maintenance is every 4 weeks by subcutaneous injection, while Skyrizi maintenance is typically every 8 to 12 weeks. Induction also differs - Omvoh uses IV infusions while Skyrizi offers both IV and subcutaneous options. Your doctor can help determine which schedule fits your lifestyle and medical situation best.

Does Omvoh work if anti-TNF therapy failed?

Yes, the VIVID-1 trial included patients who had inadequate response to or were intolerant of anti-TNF biologics, and mirikizumab demonstrated efficacy in this population (1). IL-23 inhibitors work through a completely different mechanism than anti-TNFs, so failure of one class does not predict failure of the other.

Is Omvoh covered by insurance?

Coverage varies by insurance plan and country. In the United States, some plans may require step therapy - meaning you try (and fail) certain treatments before the insurer will approve an IL-23 inhibitor. Eli Lilly's Omvoh Together program can help with copay support for commercially insured patients. Outside the US, access depends on your national formulary and reimbursement pathways. Talk to your GI team about navigating coverage in your situation.

What should I ask my doctor about Omvoh?

Consider asking: "Is my current disease activity severe enough to qualify for this treatment?" "Given my biologic history, would Omvoh be a first- or second-line choice?" "What screening tests do I need before starting?" "How will we monitor for liver enzyme changes during treatment?" and "What is your experience with patients transitioning from my current biologic to this one?" Having specific questions ready will help you and your doctor make the most informed decision together.

References

1. D'Haens, G, et al. Efficacy of Mirikizumab in Moderate-to-Severe Crohn's Disease (VIVID-1 Study). Gutsandgrowth.com, 2024. Read study
2. D'Haens, G, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (VIVID-1). The Lancet, 2024. Read study
3. Eli Lilly and Company. Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz). PR Newswire, 2026. Read article
4. Loftus, E, et al. Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study. PubMed Central, 2025. Read study
5. Ghosh, S, et al. Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study. PubMed, 2025. Read study
6. Medscape. Omvoh (mirikizumab) dosing, indications, interactions, adverse effects, and more. 2025. View on Medscape
7. Eli Lilly and Company. FDA approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease. PR Newswire, 2025. Read article